EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 28 / No 5 (Mai 2012) Med Sci (Paris), 28 5 (2012) 534-542 References
Issue
Med Sci (Paris)
Volume 28, Number 5, Mai 2012
Pionniers de la découverte de substances naturelles à activité thérapeutique
Page(s) 534 - 542
Section Forum
DOI https://doi.org/10.1051/medsci/2012285020
Published online 30 May 2012
  1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012 ; 75 : 311–335. [Google Scholar]
  2. Potier P. Étude chimique de la lunarine, alcaloïde de Lunaria biennis Moench, crucifères. Thèse pour obtenir le grade de Docteur ès sciences, soutenue le 21 décembre 1960, Paris, CDU et SEDES. [Google Scholar]
  3. Cave A, Kan-Fan C, Potier P, Le Men J. Modification de la réaction de Polonovski : action de l’anhydride trifluoroacétique sur un aminoxyde. Tetrahedron 1967 ; 23 : 4681–4689. [CrossRef] [Google Scholar]
  4. Svoboda GH, Johnson IS, Gorman M, Neuss N. Current status of research on the alkaloids of Vinca rosea Linn. (Catharanthus roseus G. Don). J Pharm Sci 1962 ; 51 : 707–720. [CrossRef] [PubMed] [Google Scholar]
  5. Noble RL, Beer CT, Cutts JH. Role of chance observations in chemotherapy: Vinca rosea. Ann NY Acad Sci 1958 ; 76 : 882–894. [CrossRef] [Google Scholar]
  6. Cutts JH, Beer CT, Noble RL. Biological properties of vincaleukoblastine, an alkaloid in Vinca rosea Linn, with reference to its antitumor action. Cancer Res 1960 ; 20 : 1023–1031. [PubMed] [Google Scholar]
  7. Noble RL. The discovery of the vinca alkaloids: chemotherapeutic agents against cancer. Biochem Cell Biol 1990 ; 68 : 1344–1351. [CrossRef] [PubMed] [Google Scholar]
  8. Langlois N, Gueritte F, Langlois Y, Potier P. Application of a modification of the Polonovski reaction to the synthesis of vinblastine-type alkaloids. J Am Chem Soc 1976 ; 98 : 7017–7024. [CrossRef] [PubMed] [Google Scholar]
  9. Mangeney P, Andriamialisoa RZ, Langlois N, et al. New class of anti-tumor compounds: 5’-nor and 5’, 6’-seco derivatives of vinblastine-type alkaloids. J Org Chem 1979 ; 44 : 3765–3768. [CrossRef] [PubMed] [Google Scholar]
  10. Zavala F, Guénard D, Potier P. Interaction of vinblastine analogues with tubulin. Experientia 1978 ; 34 : 1479–1479. [CrossRef] [Google Scholar]
  11. Piccirillo MC, Daniele G, Di Maio M, et al. Vinorelbine for non-small cell lung cancer. Expert Opin Drug Saf 2010 ; 9 : 493–510. [CrossRef] [PubMed] [Google Scholar]
  12. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971 ; 93 : 2325–2327. [CrossRef] [PubMed] [Google Scholar]
  13. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979 ; 277 : 665–667. [CrossRef] [PubMed] [Google Scholar]
  14. Gigant B, Cormier A, Dorléans A, et al. Microtubule-destabilizing agents: structural and mechanistic insights from the interaction of colchicine and vinblastine with tubulin. Top Curr Chem 2009 ; 286 : 259–278. [CrossRef] [PubMed] [Google Scholar]
  15. Gueritte-Voegelein F, Senilh V, David B, et al. Chemical studies of 10-deacetyl baccatin-III Hemisynthesis of taxol derivatives. Tetrahedron 1986 ; 42 : 4451–4460. [CrossRef] [Google Scholar]
  16. Mangatal L, Adeline M-T, Guénard D, et al. Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron 1989 ; 45 : 4177–4190. [CrossRef] [Google Scholar]
  17. Guénard D, Gueritte-Voegelein F, Lavelle F. Taxoids: a new class of antimitotic compounds. Curr Pharm Des 1995 ; 1 : 95–112. [Google Scholar]
  18. Guénard D, Guéritte F, Potier P. Anticancer natural products: Navelbine® and Taxotère®. Actual Chim 2003 ; 4–5 : 89–92. [Google Scholar]
  19. Kansal VK, Potier P. The biogenetic, synthetic and biochemical aspects of ellipticine, an antitumor alkaloid. Tetrahedron 1986 ; 42 : 2389–2408. [CrossRef] [Google Scholar]
  20. Goodwin S, Smith AF, Horning EC. Alkaloids of Ochrosia elliptica Labill. J Am Chem Soc 1959 ; 81 : 1903–1908. [CrossRef] [Google Scholar]
  21. Woodward RB, Iacobucci GA, Hochstein FA. The synthesis of ellipticine. J Am Chem Soc 1959 ; 81 : 4434–4435. [CrossRef] [Google Scholar]
  22. Dalton LK, Demerac S, Elmes BC, et al. Synthesis of the tumour-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido[4, 3-b] carbazoles. Aust J Chem 1967 ; 20 : 2715–2727. [CrossRef] [Google Scholar]
  23. Hayat M, Mathé G, Janot MM, et al. Experimental screening of 3 forms and 19 derivatives or analogs of ellipticine: oncostatic effect on L1210 leukaemia and immunosuppressive effect of 4 of them. Biomedicine 1974 ; 21 : 101–106. [PubMed] [Google Scholar]
  24. Paoletti C, Le Pecq JB, Dat Xuong N, et al. New anticancer derivatives in the ellipticine series. In : Siegenthaler W, Luthy R, eds. Current chemotherapy. Washington : ASM, 1978 : 1195–1197. [Google Scholar]
  25. Prudent R, Moucadel V, Nguyen CH, et al. Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2. Cancer Res 2010 ; 70 : 9865–9874. [CrossRef] [PubMed] [Google Scholar]
  26. Prudent R, Hasenknopf B, Cochet C. Les polyoxométallates :des inhibiteurs inorganiques de la protéine kinase CK2. Med Sci (Paris) 2008 ; 24 : 1012–1014. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  27. Ahond A, Zurita MB, Colin MF, et al. Girolline, a new antitumoral compound extracted from the sponge, Pseudaxinyssa cantharella (Axinellidae). CR Acad Sci Ser II 1988 ; 307 : 145–148. [Google Scholar]
  28. Colson G, Rabault B, Lavelle F, Zerial A. Mode of action of the antitumor compound girodazole (RP 49532A, NSC 627434). Biochem Pharmacol 1992 ; 43 : 1717–1723. [CrossRef] [PubMed] [Google Scholar]
  29. Diop D, Chauvin C, Salhi S, et al. Girolline interferes with cell-cycle progression, but not with translation. CR Biologies 2007 ; 330 : 855–860. [CrossRef] [Google Scholar]
  30. Lavelle F, Zerial A, Fizames C, et al. Antitumor activity and mechanism of action of the marine compound girodazole. Invest New Drugs 1991 ; 9 : 233–244. [PubMed] [Google Scholar]
  31. Catimel G, Coquard R, Guastalla JP, et al. Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors. Cancer Chemother Pharmacol 1995 ; 35 : 246–248. [CrossRef] [PubMed] [Google Scholar]
  32. Potier P, Chast F. Le magasin du Bon Dieu. Les extraordinaires richesses thérapeutiques des plantes et des animaux. Paris : JC Lattès, 2001 : 286 p. [Google Scholar]
  33. Bernier JC, Potier P. Un chimiste trouveur. L’Actualité Chimique 2006 ; 299 : 3–6. [Google Scholar]
  34. Le Roux M. Hommage à Pierre Potier (1934-2006). Dépasser les limites du présent. Rayonnement du CNRS 2006 ; 41 : 5–27. [Google Scholar]
  35. Calvo F, Le Roux M. De l’intuition à l’audace, l’œuvre de Pierre Potier. La Revue pour l’Histoire du CNRS 2006 ; 14. [Google Scholar]
  36. Mouchet S. Pierre Potier. Med Sci (Paris) 2006 ; 22 : 492. [EDP Sciences] [Google Scholar]
  37. Archives du CNRS : Dossier G 990001 DOC. CNRS, 53, Pierre Potier, Médaille d’or du CNRS, 1998. [Google Scholar]
  38. Bohuon C, Monneret C. Fabuleux hasards : histoire de la découverte de médicaments. Paris : EDP Sciences, 2009 : 140 p. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.